Diagnosis & Disease Information

Prostate Cancer CTC PSMA Status Could Guide Therapy

October 5, 2022

PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.

Lymphoma

PLM60 Plus Pegaspargase Shows Promise in Extranodal Natural Killer and T-Cell Lymphoma

Jonathan Goodman, MPhil

October 5, 2022

Researchers sought to determine whether PLM60 with pegaspargase would have efficacy in patients with extranodal natural killer/T-cell lymphoma.

Pancreatic Cancer

Liposomal Irinotecan Improves Upon 5-FU/LV in Refractory Pancreatic Cancer

Andrea S. Blevins Primeau, PhD, MBA

October 4, 2022

Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.

Prostate Cancer

Novel Hormonal Therapies for nmCRPC Underused, Data Show

Jody A. Charnow

September 30, 2022

Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.

Next post in Prostate Cancer

Diagnosis & Disease Information

Prostate Cancer CTC PSMA Status Could Guide Therapy

PLM60 Plus Pegaspargase Shows Promise in Extranodal Natural Killer and T-Cell Lymphoma

Liposomal Irinotecan Improves Upon 5-FU/LV in Refractory Pancreatic Cancer

Novel Hormonal Therapies for nmCRPC Underused, Data Show

PRESTO: ADT Intensification Prolongs PSA PFS in Biochemically Recurrent Prostate Cancer